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We investigated themechanisms of resistance to carbapenems, aminoglycosides, glycylcyclines, tetracyclines, and quinolones in 90
multiresistant clinical strains ofAcinetobacter baumannii isolated from two genetically unrelatedA. baumannii clones: clone PFGE-
ROC-1 (53 strains producing theOXA-58-lactamase enzyme and 18 strainswith theOXA-24-lactamase) and clone PFGE-HUI-1
(19 strains susceptible to carbapenems).Weused real-time reverse transcriptase PCR to correlate antimicrobial resistance (MICs)with
expression of genes encoding chromosomal-lactamases (AmpCandOXA-51), porins (OmpA,CarO,Omp33,Dcap-like,OprB,
Omp25,OprC,OprD, andOmpW), and proteins integral to six efflux systems (AdeABC,AdeIJK, AdeFGH,CraA, AbeM, andAmvA).
Overexpression of the AdeABC system (level of expression relative to that byA. baumanniiATCC17978, 30- to 45-fold) was signifi-
cantly associatedwith resistance to tigecycline,minocycline, and gentamicin and other biological functions.However, hyperexpression
of the AdeIJK efflux pump (level of expression relative to that byA. baumanniiATCC17978, 8- to 10-fold) was significantly associated
onlywith resistance to tigecycline andminocycline (towhich theTetB efflux systemalso contributed). TetB andTetA(39) efflux pumps
were detected in clinical strains andwere associatedwith resistance to tetracyclines and doxycycline. The absence of theAdeABC sys-
temand the lack of expression of othermechanisms suggest that tigecycline-resistant strains of the PFGE-HUI-1 clonemay be associ-
atedwith a novel resistance-nodulation-cell efflux pump (decreasedMICs in the presence of the inhibitor Phe-Arg-naphthylamide
dihydrochloride) and theTetA(39) system.
Acinetobacter baumannii is an important pathogen that causesnosocomial infections associated with high morbidity and
mortality (1).Multidrug-resistant (MDR) strains ofA. baumannii
have emerged in the last few decades as a result of the combination
of two main factors: (i) a high level of genomic plasticity (2) and
(ii) mutation of endogenous genes, alteration of which is associ-
ated with antimicrobial resistance, such as overexpression of the
chromosomally encoded ADC -lactamase (AmpC) (3) and the
OXA-51-like -lactamase (4), loss of expression of porins (CarO
and Omp33) (5, 6), mutation in the gyrA and parC genes (7), and
overexpression of efflux systems (8).
Overexpression of the OXA-51-like -lactamase has been as-
sociated with resistance to carbapenems and decreased expression
of CarO and Omp33 (5, 6, 9).
Efflux pumps have multifactorial roles. These mechanisms are
important for detoxification of intracellular metabolites, bacterial
virulence (in both animal and plant hosts), intercellular signaling
and trafficking, and cell homeostasis (10). Three resistance-nod-
ulation-cell division (RND) systems, AdeABC, AdeIJK, and Ad-
eFGH, have been characterized and reported to cause MDR in A.
baumannii (8). AdeABC is the RND system most frequently in-
volved in MDR in clinical strains; it has been found in approxi-
mately 80% of clinical isolates (the rates reported vary from 53%
to 97%) (11) but was not detected in 32 environmental isolates
(12). AdeRS is a two-component system that regulates AdeABC
expression (13). Mutations in this system and the presence of an
ISAba1 insertion sequence in this system can lead to overexpres-
sion of the AdeABC operon (13–15). However, strains of A. bau-
mannii that express AdeABC without mutations have been found
in association with AdeRS (16, 17). Recently, the adeN gene has
been found to be associated with the regulation of the AdeIJK
system (18), and mutations in the adeL gene have been associated
with overexpression of the AdeFGHpump (11). Three other types
of efflux systems have been described in A. baumannii: CraA (a
major facilitator superfamily [MFS] pump), which confers intrin-
sic chloramphenicol resistance (19); AbeM (amember of themul-
tidrug and toxic compound extrusion [MATE] family of pumps),
which extrudes several antimicrobials and biocides (20); and
AmvA (an MFS pump), which confers resistance to detergents,
disinfectants, dyes, and erythromycin. Overexpression of the
AmvA efflux pump has been associated with increased drug resis-
tance in A. baumannii clinical isolates (21). Finally, several tetra-
cycline efflux pumps (systems acquired from the MFS superfam-
ily) have been described in A. baumannii. The most prevalent of
these are TetA, which is associated with resistance to tetracycline,
and TetB, which is implicated in resistance to tetracycline, doxy-
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cycline, and minocycline (8). TetA(39) is an important tetracy-
cline resistance mechanism in clinical strains (22).
Because of the complexity of clinical strains of A. baumannii,
many researchers have used ATCC reference strains to investigate
the mechanisms of resistance. However, very few studies have an-
alyzed the combinations of mechanisms and their interrelation in
clinical isolates of Acinetobacter baumannii. Here, we studied the
interplay between themechanisms ofmultidrug resistance in clin-
ical A. baumannii strains, particularly those involving efflux
pumps, the influx of antimicrobials, and chromosomally encoded
-lactamases.
MATERIALS AND METHODS
Bacterial isolates and molecular typing. In 2010, 444 strains of A. bau-
manniiwere isolated (from 273 patients) in 42 participating hospitals and
identified as part of the second multicenter study on this pathogen in
Spain (GEIH-REIPI-2010-Ab) (23). The strains were identified by ma-
trix-assisted laser desorption ionization–time of flight (MALDI-TOF)
mass spectrometry (24) and amplified rRNA gene restriction analysis
(ARDRA) (25). Species identification was confirmed by detection of the
OXA-51 gene by PCR (26) and also by detection of the bsp gene (a novel
target) by real-time quantitative PCR (27, 28).
The clonal relationship between all strains displaying various levels of
antibiotic susceptibility (n 71) from a hospital in southern Spain and a
hospital in the Canary Islands (n 19) was determined by pulsed-field gel
electrophoresis (PFGE) (29, 30) of samples of chromosomal DNA di-
gested with ApaI (Roche, Mannheim, Germany) and embedded in low-
melting point agarose. The restriction fragments thus obtained were sep-
arated in a CHEF DR-III system (Bio-Rad, Hercules, CA). FPQuest II
software, version 4.5 (Bio-Rad), was used to analyze the band patterns in
the agarose gel electrophoresis images (cutoff  85%). Strains of both
clones were analyzed by multilocus sequence typing, according to the
system developed by Nemec and coworkers (31).
Susceptibility testing. The antibiotic susceptibility profile was deter-
mined according to CLSI recommendations (23). In strains of the PFGE-
HUI-1 clone, we determined MICs in the presence of Phe-Arg -naph-
thylamide dihydrochloride (PAbetaN; a commonly assumed inhibitor of
the RND efflux pump) (32).
DNA amplifications studies.Weused PCR to detect the genes coding
for common aminoglycoside-modifying enzymes (AacA4, AacC1, AacC2,
AadB, AadA1, AphA1, AphA6, and AadA2) (33); CHDL enzymes (OXA-
23, -24, -51, -58, and -143) (34, 35); MBL enzymes (IMP, VIM, SPM-1,
GIM-1, SIM-1, BIC, DIM, and NDM) (36); extended-spectrum -lacta-
mases (ESBLs), such as GES enzymes; and carbapenemases, such as KPC
enzymes. We sequenced the gyrA and parC genes to study the presence of
themutations. Finally, we analyzed the tet genesmost commonly detected
in isolates of A. baumannii [tetA, tetB, tetA(34), and tetA(39)] (37, 38).
Real-time RT-PCR studies. We used real-time reverse transcriptase
PCR (RT-PCR) to examine all isolates for expression of adeB, adeJ, adeG,
abeM, craA, and amvA (genes belonging to efflux pumps systems); oprC,
oprD, ompW, ompA,carO, omp33, dcap-like, oprB, and omp25 (genes har-
boring porins or outer membrane protein); and finally, the OXA-51 and
ampC -lactamase genes. We obtained DNase-treated RNA from late-
log-phase cultures (optical density 0.4 to 0.6 absorbance units) by using
a High Pure RNA isolation kit (Roche, Germany) and 50 ng of RNA.
Analysis of controls without reverse transcriptase confirmed the absence
of contaminating DNA in the samples. We used a LightCycler 480 RNA
master hydrolysis probe (Roche, Germany) for the RT-PCR studies. The
Universal Probe Library (UPL) TaqMan probes (Roche, Germany) and
primers used are listed in Table 1. All were designed from conserved
regions ofDNAafter the alignment of the genomes of the following strains
of A. baumannii: AB 307-0294, AB 0057, ACICU, SDF, AYE, and ATCC
17978. We adjusted the concentrations of the samples to achieve efficien-
cies of 90% to 110% and performed all experiments in triplicate from
three RNA extractions. For each strain, we normalized the levels of ex-
pression of all genes relative to those of the single-copy housekeeping
genes rpoB and gyrB. We then calibrated the normalized expression of
each gene of interest relative to its expression by A. baumannii ATCC
17978, which was assigned a value of 1.0.
Sequencing of the genes regulating AdeABC and AdeIJK efflux
pumps. We sought mutations in the regulatory genes adeR-adeS and
adeN, which have previously been associated with upregulation of the
AdeABC and AdeIJK efflux systems, respectively. We amplified the genes
by using the primers listed in Table 1. We used the Macrogen program
(Macrogen Europe, Amsterdam, Netherlands) for DNA sequencing and
the NCBI BLAST (www.ncbi.nlm.gov/BLAST) and CLUSTAL (www.ebi
.ac.uk/Tools/msa/clustalw2/) programs for posterior analyses.
Statistical analysis. We categorized the strains into two groups ac-
cording to antimicrobial susceptibility (not following the CLSI or
EUCAST clinical breakpoints). We worked with the Student’s t test to
compare differences in gene expression between groups and thus evaluate
any associations with antibiotic resistance. Differences were considered
significant at a P value of0.05.
Nucleotide sequence accession numbers. The nucleotide sequences
of the adeR, adeS, and adeN genes from strains of the PFGE-ROC-1 clone
were submitted to the GenBank database and have been assigned acces-
sion numbers KF147860, KF147861, and KF147862, respectively.
RESULTS
MICs, typing, and PCR detection of genes of the isolates. To
study the expression levels of efflux pump systems, porins, and chro-
mosomal -lactamases, we selected clonally related strains with dif-
ferent antibiotic susceptibilities (39). In Spain, OXA-type enzymes
are prevalent in carbapenem-resistant strains of A. baumannii (40,
41). Isolates ofA. baumannii fromtwohospitals in Spain that showed
some clonal relation were designated clone PFGE-ROC-1 (sequence
type2 [ST2]) (n71;Fig. 1) andclonePFGE-HUI-1 (ST79) (n19;
Fig. 2). Moreover, 53 strains of the PFGE-ROC-1 clone carried the
OXA-58 -lactamase gene (designated PFGE-ROC-1OXA-58; imi-
penem MICs, 8 to 64 mg/liter; meropenem MICs, 8 to 16 mg/liter)
and 18 isolates carried the OXA-24 -lactamase gene (designated
PFGE-ROC-1OXA-24; imipenem MICs, 64 mg/liter; meropenem
MICs, 32 to 64mg/liter). The isolates of clonePFGE-HUI-1 (n 19)
were susceptible to carbapenems. We studied the variability in the
MICs of glycylcyclines, aminoglycosides, tetracyclines, rifampin, and
doripenem for all isolates, with the following results: (i) for PFGE-
ROC-1OXA-58 (Table 2) tigecycline MICs were 0.25 to 2 mg/liter,
gentamicinMICswere 1 to64mg/liter, amikacinMICswere2 to
64mg/liter, doxycyclineMICs were 16 to64mg/liter, minocycline
MICs were 1 to 8 mg/liter, tetracycline MICs were 64 mg/liter,
netilmicinMICswere 1 to64mg/liter, rifampinMICswere 1 to 64
mg/liter, tobramycin MICs were 0.5 to 64, and doripenem MICs
were 4 to 8 mg/liter. (ii) For PFGE-ROC-1OXA-24 (Table 3), tigecy-
clineMICswere0.25 to 1mg/liter, gentamicinMICswere 2 to64
mg/liter, amikacin MICs were2 to 64 mg/liter, doxycycline MICs
were 16 to 32 mg/liter, minocycline MICs were 0.5 to 4 mg/liter,
tetracycline MICs were 64 mg/liter, netilmicin MICs were 64 to
64 mg/liter, rifampin MICs were 0.5 to 4 mg/liter, tobramycin
MICs were 4 to 64 mg/liter, and doripenem MICs were 64 to 64
mg/liter. (iii) For PFGE-HUI-1 (Table 4), tigecyclineMICs were 1 to
2 mg/liter, gentamicin MICs were 16- to 64 mg/liter, amikacin
MICs were 4 to 64 mg/liter, doxycycline MICs were 0.5 to 8 mg/
liter, minocycline MICs were 0.5 to 1 mg/liter, tetracycline MICs
were 4 to 64 mg/liter, netilmicin MICs were 4 to 64 mg/liter,
rifampinMICs were 2 to 32mg/liter, tobramycinMICs were 8 to 64
mg/liter, and doripenemMICs were0.5 to 2mg/liter.
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We detected tet genes in both clones: the tetB gene in all strains
of PFGE-ROC-1 and the tetA(39) gene in strains of the PFGE-
HUI-1 clone (except for strains 421, 422, 423, 424, and 426).
In both A. baumannii clones, we detected the AacC1/AphA1/
AadB combination of acetylases in strains displaying some resis-
tance to aminoglycosides. We also detected mutations in the gyrA
(Ser83¡ Leu) and parC (Ser80¡ Leu) genes in strains showing
resistance to quinolones.
Relative gene expression.The levels of expression of the efflux
pump genes in the isolates relative to that by A. baumannii ATCC
17978 (relative expression ([RE] values) are shown in Tables 2 to
4. For clone PFGE-ROC-1, we applied statistical analysis to genes
with RE values higher than 8 (i.e., genes adeB and adeJ) to deter-
mine how gene expression was related to the antibiotic MICs (for
strains carrying the OXA-58 -lactamase gene, see Fig. 3; for
strains carrying the OXA-24 -lactamase gene, see Fig. 4). How-
ever, we were not able to analyze the adeB gene in strains of clone
PFGE-HUI-1, because the internal and external primers used did
not amplify the genes in the AdeABC operon of these strains.
Moreover, the relative expression of adeJ in this clone was not
higher than 2.
The RE values of adeG, craA, abeM, and amvA in all strains
ranged from 0.003 to 1.
Porin expression was not significantly related to antibiotic re-
sistance in strains of clone PFGE-ROC-1 or PFGE-HUI-1. How-
ever, in strains of clone PFGE-ROC-1OXA-24, the RE values of the
carO and omp25 genes were lower than those in strains of clone
PFGE-ROC-1OXA-58 (Fig. 5). However, the RE values of the
OXA-51 and ampC -lactamase genes were similar among the
isolates.
Polymorphisms of the regulatory genes of the AdeABC and
AdeIJK efflux pumps. Strains of the PFGE-ROC-1 clone that
overexpressed the AdeABC efflux pump had three mutations in
the adeS gene (Ala94¡Val, Gly186¡Val, and Phe214¡ Leu) and
TABLE 1 Primers used in this study
Analysis and gene Orientation Primer sequence (5=–3=) UPL probea Reference or source
RT-PCR analysis
rpoB Forward CGTGTATCTGCGCTTGG 131 This study
Reverse CGTACTTCGAAGCCTGCAC
gyrB Forward TGGTGGAACGTGGTCATATTT 76 This study
Reverse TGCTCTTGCTTACCCTTTTTG
adeB Forward CGAGTGGCACAACTAGCATC 61 This study
Reverse CCTTGTCTTGGCTGCACTCT
adeJ Forward CCTATTGCACAATATCCAACGA 119 This study
Reverse AGGATAAGTCGCAGCAATCG
adeG Forward GTCCTGAAATGGTCGTTCGT 43 This study
Reverse AGCTTCTGCTTGGCTAGATGA
craA Forward TTCATTGCTTGCGCCTTT 125 This study
Reverse CCAGTGCCATGAAACATAATCA
abeM Forward AGGGACGTATTATGGCGAAA 165 This study
Reverse CTGCTGTGCTTAGACCAATTTTT
amvA Forward GCAGAGAAATTTTGCACTTGG 10 This study
Reverse CGACTAATGGACCAAAAGCTG
ompA Forward GGTATTCAGATAATTTTTCAGCAACTT 129 This study
Reverse AACAAATCAAACATCAAAGACCAA
ompW Forward GCCTTATTTGCTCTGCCAAC 60 This study
Reverse CGTTTGAAACCATCACCATCT
dcap-like Forward TGATCGACTTCTCGACAAACA 77 This study
Reverse GTGTAGTTGGGCCTAGTTTGTAGTT
oprC Forward ACTCGATACAAAGCGGTGGA 9 This study
Reverse TTTAATACGTGAACCAAACATACCTC
oprB Forward GCCCCACACTTCTTGAACAG 67 This study
Reverse ATGGGCAATCGCTTTCTG
omp25 Forward CGAACGTGAAATCGACAACA 128 This study
Reverse CGTAACCTTTAACACCTAGAGCAAG
omp33-omp36 Forward CAAGTGTTGCTAACCAATTCGCT FAM-CCAAACTGCTGCTATCCAAAA
CGACCAA-BBQ
This study
Reverse GTTTTCTTGACCGAATGCACC
carO Forward TGTTCATGACAGCTATGCATTCGATA FAM-CGCTCGTGCTGAAGTAGGTAC
TACAGGTT-BBQ
This study
Reverse CCCAATGCTAAACCTACATATGGGT
Sequencing analysis
adeR Forward ACTACGATATTGGCGACATT
Reverse GCGTCAGATTAAGCAAGATT 13–15
adeS Forward TTGGTTAGCCACTGTTATCT
Reverse AGTGGACGTTAGGTCAAGTT 13–15
adeN Forward GCTGTTAGGTTGGGGTCGTA
Reverse CGTGACCAAAAGTACGAATCA 18
a FAM, 6-carboxyfluorescein; BBQ, BlackBerry Quencher.
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FIG 1 Pulsed-field electrophoresis of strains of the PFGE-ROC-1 clone. REP-PCR, repetitive element palindromic PCR.
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onemutation in the adeR gene (Ala136¡Val). Only two strains of
this clone had mutations in the adeN regulatory gene in the Ad-
eIJK efflux pump (His111¡Pro, Ile112¡Phe). The adeS and adeR
genes in strains of clone PFGE-HUI-1 were not successfully am-
plified. In all strains of this clone, the adeN gene had onemutation
(Pro16¡ Lys).
Relation between relative gene expression and MICs. Possi-
ble interactions between the mechanisms of resistance of the clin-
ical strains of the two clones are summarized in Table 5.
(i) Carbapenems. For the carbapenems (imipenem, mero-
penem, and doripenem), resistance was associated with the pres-
ence of the OXA-type enzymes (OXA-24 andOXA-58-lactama-
ses) in strains of clone PFGE-ROC-1.
(ii) Aminoglycosides. Ingentamicin-resistant strains (MICs8
mg/liter) of clone PFGE-ROC-1, the AdeABC system was overex-
pressed and/or acetylases (AacC1/AphA1/AadB) were present.
Moreover, in strains of both clones (PFGE-ROC-1 and PFGE-
HUI-1), the presence of acetylases (AacC1/AphA1/AadB) was as-
sociated with resistance to netilmicin (MICs  16 mg/liter), to-
bramycin (MICs  8 mg/liter), and amikacin (MICs  16 mg/
liter).
(iii) Glycylcyclines. Resistance to tigecycline (MICs 0.5 mg/
liter) was associated with overexpression of the RND systems
(AdeIJK efflux pump in PFGE-ROC-1OXA58 [Fig. 3] and
AdeABC efflux pump in PFGE-ROC-1OXA24 [Fig. 4]) and the
TetA(39) effux pump. The presence of PAbetaN (an inhibitor of
the RND system) in strains of clone PFGE-HUI-1 was associated
with decreased resistance to tigecycline. In the strains of this clone
with noTetA efflux pump (strains 421, 422, 423, 424, and 426), the
tigecycline MIC decreased from 1 to 0.25 mg/liter (with PA-
betaN). In those strains of clone PFGE-HUI-1 with a TetA system,
the tigecyclineMIC decreased from 2 to 1mg/liter in the presence
of PAbetaN. The AdeIJK and AdeABC efflux pumps (in strains of
clone PFGE-ROC-1) were associated with resistance to minocy-
cline (MICs 2 mg/liter). However, PFGE-ROCOXA-58 displayed
resistance to this antibiotic, possibly because of overexpression of
the AdeIJK and TetB efflux pumps.
(iv) Tetracyclines. Resistance to tetracyclines was associated
with TetB and TetA(39) efflux pumps. In doxycycline-resistant
isolates (strains of PFGE-ROC-1OXA-58 with MICs of 16 mg/
liter), AdeIJK was overexpressed together with Tet systems.
(v) Quinolones. Finally, mutations of the gyrA and parC genes
conferred resistance to ciprofloxacin without any variations in
MICs.
DISCUSSION
The impact of the interplay between different mechanisms of an-
timicrobial resistance in the susceptibility or resistance to antibi-
otics has been addressed in previous studies. Here, we focused on
two of these studies in relation to the present study. One of these
studies involved clinical strains of P. aeruginosa isolated from cys-
tic fibrosis patients (representative of the Liverpool epidemic
strain) (39), and the other involved strains isolated from blood-
stream infections (40). In the present study, we attempted to de-
termine if similar conclusions can be applied to clinical strains of
A. baumannii in which resistance is associated with a multifacto-
rial mechanism. We analyzed strains of two different clones,
PFGE-ROC-1 and PFGE-HUI-1. The PFGE-ROC-1 clone in-
cluded 53 strains carrying the OXA-58 -lactamase gene (PFGE-
ROC-1OXA-58) and 18 strains carrying the OXA-24 carbapen-
emase gene (PFGE-ROC-1OXA-24). The enzymes encoded by both
of these genes are highly prevalent in isolates of A. baumannii in
FIG 2 Pulsed-field electrophoresis of strains of the PFGE-HUI-1 clone.
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the Iberian Peninsula (41, 42). Only strains of the PFGE-HUI-1
clone (n  19 strains) have previously shown susceptibility to
carbapenems (23).
Overexpression of theAdeABC system (RE, 30- to 45-fold)was
significantly associated with resistance to gentamicin (MICs  8
mg/liter) in strains of PFGE-ROC-1 (which produce the OXA-58
and OXA-24 -lactamases) (8). Moreover, in strains of PFGE-
ROC-1OXA-24, resistance to tigecycline (MICs 0.5 mg/liter) and
minocycline (MICs 2mg/liter) was also significantly associated
with expression of this efflux pump, as previously reported (8). All
strains of the PFGE-ROC-1 clone had mutations in the adeR
(Ala136 ¡ Val) and adeS (Ala94 ¡ Val, Gly186 ¡ Val, and
Phe214¡ Leu) genes. Hornsey et al. associated the Ala94¡ Val
substitution with overexpression of the AdeABC efflux pump in
A. baumannii strains representative of the prevalent United King-
dom lineage, OXA-23 clone 1 (16, 43). However, the other muta-
tions have not previously been described. Peleg et al. (17) reported
that increased (40- to 54-fold) expression of the adeB gene was
TABLE 2 MICs and RE of genes harboring efflux pumpsc
Straina
MICd (mg/liter) REb
TIG GEN AMK DOX MIN NET TET RIF TOB DOR adeB adeJ adeG craA abeM amvA
65 0.25 8 2 16 2 1 64 2 1 4 1.13 3.10 1.00 0.43 0.21 0.002
34 0.5 2 32 32 2 64 64 64 32 8 27.73 0.55 0.70 1.31 0.60 0.003
35 0.5 4 16 32 2 64 64 64 64 8 31.97 0.40 0.82 1.12 0.66 0.003
37 0.5 4 16 32 2 64 64 64 32 8 28.10 0.42 0.70 1.25 0.78 0.003
41 0.5 4 32 16 2 64 64 64 64 4 26.89 0.57 0.66 1.34 0.50 0.003
51 0.5 4 16 32 4 64 64 64 64 8 16.21 1.62 0.41 0.65 0.70 0.004
53 0.5 4 16 32 4 64 64 64 32 8 17.03 1.06 0.49 0.70 0.48 0.003
55 0.5 4 16 32 4 64 64 64 64 8 18.25 1.38 0.85 0.64 0.37 0.004
57 0.5 4 16 32 4 64 64 64 64 8 10.43 4.69 0.37 0.70 0.78 0.003
78 0.5 32 2 16 2 4 64 64 0.5 4 23.88 5.44 0.96 1.14 0.40 0.007
88 0.5 4 32 16 2 64 64 32 32 4 11.77 6.60 0.92 0.73 0.24 0.003
118 0.5 32 16 32 2 64 64 32 64 4 35.08 0.61 1.31 0.64 0.27 0.003
126 0.5 16 2 2 4 4 64 32 0.5 4 1.77 1.06 1.27 0.64 0.32 0.004
36 1 4 16 32 2 64 64 64 64 4 32.25 0.61 0.80 1.03 0.69 0.004
38 1 4 32 32 2 64 64 64 64 8 30.51 1.34 0.78 1.14 0.51 0.002
58 1 4 32 32 4 64 64 64 64 8 26.93 2.20 0.44 0.85 0.45 0.005
83 1 2 32 32 4 64 64 64 32 4 33.76 7.98 1.37 0.80 0.19 0.002
84 1 2 32 32 4 64 64 64 64 4 13.45 10.02 1.08 0.85 0.24 0.003
86 1 64 8 32 4 32 64 2 2 4 22.39 6.85 0.97 0.69 0.19 0.004
87 1 64 4 64 4 16 64 2 2 4 43.48 6.82 0.92 0.67 0.08 0.003
89 1 64 4 64 4 32 64 64 64 4 7.25 5.61 1.17 0.89 0.21 0.003
90 1 2 16 64 4 64 64 64 32 8 20.86 10.33 1.00 0.72 0.23 0.004
110 1 2 16 16 4 64 64 32 64 4 30.22 5.18 1.25 0.31 0.30 0.003
111 1 2 16 16 2 64 64 32 32 4 9.86 5.39 1.55 0.31 0.21 0.003
112 1 2 8 16 2 64 64 32 32 8 11.45 3.06 1.23 0.21 0.18 0.36
113 1 2 2 32 2 4 64 32 0.5 4 24.40 4.27 0.89 0.31 0.25 0.006
114 1 1 2 32 2 4 64 32 1 4 7.01 3.87 0.77 0.27 0.26 0.004
115 1 1 2 16 2 4 64 16 0.5 4 30.32 3.13 0.82 0.75 0.19 0.003
119 1 32 16 32 2 64 64 32 32 4 43.01 0.60 1.23 0.54 0.33 0.003
120 1 32 16 16 2 64 64 32 32 4 35.43 0.66 0.75 0.65 0.19 0.003
124 1 4 64 64 4 64 64 32 64 4 46.58 0.72 0.79 0.63 0.30 0.004
125 1 4 16 32 8 64 64 64 32 4 32.77 8.97 0.45 0.70 0.30 0.005
56 2 2 2 32 4 8 64 64 1 8 21.05 5.82 0.48 0.87 0.38 0.003
64 2 64 4 32 2 16 64 2 4 4 68.98 2.94 0.36 0.62 0.21 0.004
79 2 64 4 16 1 16 64 2 2 8 37.66 12.58 1.57 0.59 0.22 0.004
80 2 64 8 32 4 32 64 1 2 8 32.70 10.77 0.97 0.63 0.19 0.002
81 2 64 4 32 4 16 64 2 2 4 46.54 11.16 0.92 0.86 0.18 0.002
82 2 64 2 32 2 16 64 1 1 4 27.63 10.04 1.00 0.97 0.15 0.002
101 2 2 16 32 4 64 64 32 32 4 12.44 4.13 1.25 0.24 0.13 0.003
102 2 2 16 32 4 64 64 32 32 4 8.91 7.26 1.17 0.36 0.28 0.005
106 2 2 8 64 8 64 64 64 32 4 12.06 10.55 1.38 0.76 0.31 0.006
107 2 2 32 64 8 64 64 64 32 4 16.38 10.80 0.91 0.25 0.32 0.004
108 2 4 32 64 8 64 64 64 32 8 23.92 10.94 1.07 0.21 0.29 0.002
109 2 4 32 64 8 64 64 64 32 8 23.37 6.32 0.68 0.32 0.22 0.003
a Strains are ranked according to the MIC of tigecycline.
b Increased gene RE values of2 are indicated in bold.
c The reference strain used was A. baumannii ATCC 17978. RNA (50 g/ml) was from strains of the PFGE-ROC-1OXA58 clone.
d TIG, tigecycline; GEN, gentamicin; AMK, amikacin; DOX, doxycycline; MIN, minocycline; NET, netilmicin; TET, tetracycline; RIF, rifampin; TOB, tobramycin; DOR,
doripenem.
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associated with tigecyclineMICs of 4 to 16mg/liter inA. bauman-
nii. We found that tigecycline-susceptible strains (MIC 0.5 mg/
liter) were associated with increased expression of the adeB gene
(about 20- to 30-fold), which could indicate the role of the
AdeABC efflux pump in others functions necessary for the patho-
genesis of clinical strains of A. baumannii, such as colonization,
infection, and the persistence of microorganisms in the host (10).
We did not detect the AdeABC efflux pump or regulator genes in
clinical strains ofA. baumannii clone PFGE-HUI-1 (susceptible to
carbapenems). Asmentioned above, this efflux pump is present in
80% (range, 53% to 97%) of clinical isolates studied so far (8).
Increased expression of the AdeIJK efflux pump (RE, 8- to
10-fold) was significantly associated with tigecycline resistance
(MICs  0.5 mg/liter) and minocycline resistance (MICs  2
TABLE 3 MICs and RE of genes harboring efflux pumpsc
Straina
MICd (mg/liter) REb
TIG GEN AMK DOX MIN TET NET RIF TOB DOR adeBb adeJ adeG craA abeM amvA
44 0.25 2 32 16 1 64 64 2 32 64 26.60 1.69 0.68 1.47 0.39 0.002
45 0.25 2 32 16 1 64 64 1 64 64 15.00 1.21 0.67 0.71 0.43 0.001
47 0.25 4 16 16 1 64 64 1 64 64 19.50 1.29 0.80 0.53 0.45 0.002
61 0.25 4 16 16 4 64 64 2 64 64 23.25 1.24 0.34 0.99 0.15 0.005
62 0.25 2 32 16 1 64 64 1 64 64 20.19 1.67 0.49 0.49 0.17 0.002
95 0.25 4 32 16 1 64 64 0.5 32 64 33.95 1.33 1.06 0.32 0.22 0.002
40 0.5 4 32 16 1 64 64 1 64 64 12.88 0.25 0.59 0.91 0.36 0.001
46 0.5 2 32 16 1 64 64 1 64 64 10.82 1.70 0.84 1.18 0.38 0.002
48 0.5 8 32 16 1 64 64 1 64 64 10.28 1.13 1.04 0.81 0.33 0.002
50 0.5 2 64 16 0.5 64 64 2 64 64 11.91 1.25 0.44 0.70 0.41 0.002
60 0.5 4 64 16 1 64 64 1 64 64 29.20 1.52 0.36 1.18 0.41 0.003
72 0.5 2 32 16 0.5 64 64 1 32 64 24.94 1.19 0.87 0.73 0.23 0.004
73 0.5 2 32 16 0.5 64 64 2 64 64 7.53 1.21 0.60 0.72 0.17 0.004
74 0.5 64 2 32 4 64 64 4 4 64 22.19 1.08 0.51 0.68 0.17 0.003
75 0.5 64 4 16 4 64 64 4 4 64 13.95 0.84 0.49 0.52 0.17 0.002
96 0.5 4 32 16 1 64 64 1 64 64 8.55 1.46 0.97 0.31 0.22 0.002
63 1 4 16 16 1 64 64 1 32 64 43.11 1.87 0.41 0.59 0.23 0.005
67 1 64 32 16 0.5 64 64 1 64 64 44.95 0.81 0.63 0.45 0.19 0.002
a Strains are ranked according to the MIC of tigecycline.
b Increased gene RE values of2 are indicated in bold.
c The reference strain used was A. baumannii ATCC 17978. RNA (50 g/ml) was from strains of the PFGE-ROC-1OXA24 clone.
d TIG, tigecycline; GEN, gentamicin; AMK, amikacin; DOX, doxycycline; MIN, minocycline; TET, tetracycline; NET, netilmicin; RIF, rifampin; TOB, tobramycin; DOR,
doripenem.
TABLE 4 MICs and RE of efflux pumpsc
Straina
MICd (mg/liter) REb
TIG GEN AMK DOX MIN TET NET RIF TOB DOR adeB adeJ adeG craA abeM amvA
421 1 64 64 0.5 0.5 4 64 2 64 1 NA 1.44 1.23 1.20 0.04 0.01
422 1 16 16 0.5 0.5 8 8 2 8 0.5 NA 1.37 2.11 0.82 0.05 0.02
423 1 16 16 0.5 0.5 8 8 2 16 1 NA 1.21 1.16 0.63 0.07 0.02
424 1 16 64 1 1 4 8 16 32 0.5 NA 1.41 0.89 0.68 0.04 0.02
426 1 64 32 1 1 8 64 16 32 0.5 NA 1.69 1.00 0.45 0.04 0.02
427 2 16 16 8 0.5 64 8 4 8 1 NA 1.46 0.83 0.42 0.04 0.02
428 2 16 16 4 0.5 64 4 2 8 1 NA 1.64 0.89 0.49 0.05 0.02
429 2 64 4 4 0.5 64 8 4 8 1 NA 1.75 0.91 0.48 0.04 0.01
430 2 32 16 8 0.5 64 16 4 16 1 NA 1.22 0.76 0.48 0.04 0.02
431 2 64 4 8 1 64 32 32 32 1 NA 1.28 1.00 0.44 0.04 0.02
432 2 16 16 4 0.5 64 4 4 16 2 NA 1.61 0.90 0.53 0.04 0.02
433 2 16 16 8 0.5 64 8 4 16 2 NA 1.51 0.89 0.54 0.04 0.02
434 2 16 16 4 0.5 64 8 4 8 2 NA 1.82 1.09 0.50 0.04 0.02
435 2 32 32 4 0.5 64 8 2 32 1 NA 1.27 0.90 0.34 0.05 0.01
436 2 16 16 8 1 64 16 4 8 1 NA 1.32 0.79 0.43 0.04 0.01
437 2 16 16 4 1 64 4 4 16 0.5 NA 0.72 1.18 0.78 0.03 0.03
438 2 32 16 8 1 64 8 4 16 0.5 NA 1.25 1.51 0.60 0.03 0.02
443 2 16 16 4 0.5 64 8 4 8 1 NA 0.91 0.80 0.52 0.04 0.01
a Strains are ranked according to the MIC of tigecycline.
b Primers for adeA and adeC genes were also used. NA, not applicable.
c The reference strain used was A. baumannii ATCC 17978. RNA (50 g/ml) was from strains of the PFGE-HUI-1 clone (susceptible to carbapenems).
d TIG, tigecycline; GEN, gentamicin; AMK, amikacin; DOX, doxycycline; MIN, minocycline; TET, tetracycline; NET, netilmicin; RIF, rifampin; TOB, tobramycin; DOR,
doripenem.
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mg/liter) in strains of PFGE-ROC-1OXA-58. However, this system
was not significantly associated with resistance to netilmicin or
tobramycin (aminoglycosides). These results are consistent with
those obtained by Coyne et al. (44). These authors also noted that
overexpression of this pump is always lower than that of the
AdeABC system. These results could confirm the theory that high-
level expression of the AdeIJK efflux pump is toxic to the host cell
(45). The adeJ gene was not overexpressed in strains of the PFGE-
ROC-1OXA-24 and PFGE-HUI-1 clones. Only two strains of the
PFGE-ROC-1OXA-58 clone had two new mutations in a gene reg-
ulating the AdeIJK pump (adeN; His111¡ Pro, Ile112¡ Phe), and
all strains of PFGE-HUI-1 had a Pro16¡ Lys substitution in the
adeN gene. None of these mutations have been associated with
overexpression of AdeIJK, although other possiblemechanisms of
regulation cannot be ruled out (18).
Expression of adeG (AdeFGH), craA, abeM, and amvAwas not
increased (RE, 0.003 to 1) in strains of the PFGE-ROC-1 or PFGE-
HUI-1 clone.
Gram-positive bacteria are the origin of tet genes detected in
Gram-negative bacteria, such as A. baumannii (22, 38). Here, we
detected the tetB gene in strains of the PFGE-ROC-1 clone, all of
which were resistant to tetracycline (MICs  16 to 64 mg/liter)
and doxycycline (MICs  16 to 64 mg/liter). Moreover, in some
strains (PFGE-ROC-1OXA-58), overexpression of AdeIJK together
with the presence of this acquired efflux pump was possibly asso-
ciated with resistance to minocycline (MICs 2 to 4 mg/liter). In
FIG 3 Relative expression of the adeB and adeJ genes from strains of the PFGE-ROC-1OXA-58 clone in relation to the MICs of different antibiotics.*, P 0.05
(Student’s t test). Light gray bars, strains susceptible to several antibiotics (grouped by MIC [in mg/liter]); dark gray bars, strains resistant to several antibiotics
(grouped by MIC [in mg/liter]); TIG, tigecycline; GEN, gentamicin; AMK, amikacin; DOX, doxycycline; MIN, minocycline; NET, netilmicin; RIF, rifampin;
TOB, tobramycin.
FIG 4 Relative expression of the adeB and adeJ genes from strains of the PFGE-ROC-1OXA-24 clone in relation to the MICs of different antibiotics.*, P 0.05
(Student’s t test). Light gray bars, strains susceptible to several antibiotics (grouped by MIC [in mg/liter]); dark gray bars, strains resistant to several antibiotics
(grouped by MIC [in mg/liter]); TIG, tigecycline; GEN, gentamicin; AMK, amikacin; DOX, doxycycline; MIN, minocycline.
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other pathogens, such as Escherichia coli, the combination of
AcrAB-TolC and TetA has been associated with a high degree of
resistance to tetracycline (46). Our results showed that detection
of the tetA(39) gene in all strains of this clone was associated with
resistance to tetracycline and doxycycline. Agersø and Guard-
abassi (47) analyzed the presence of this gene in A. baumannii
strains. These authors located the gene in both environmental and
clinical strains, and they found the tetA(39) gene in 33 tigecycline-
resistant strains (MICs 16mg/liter). We noted that in strains of
PFGE-HUI-1 harboring the tetA(39) gene, the tigecycline MIC
was lower (2 to 1 mg/liter) in the presence of PAbetaN (an RND
efflux pump inhibitor), and the MIC decreased from 1 to 0.25
mg/liter in the A. baumannii strains without this gene. This sug-
gests the involvement of a new RND efflux pump, together with
the TetA(39) system, in the resistance to tigecycline.
In relation to porins and unlike in other pathogens, such as
Pseudomonas aeruginosa, in which OprD expression plays an im-
portant role in resistance to carbapenem antibiotics (39), we
found that decreased expression of a porin was significantly asso-
ciated with antimicrobial resistance. We observed decreased RE
only of the carO and omp25 genes, on comparing strains of PFGE
clone-ROC-1OXA-58 and PFGE clone-ROC-1OXA-24. This decrease
was not associated with resistance to carbapenems, which is
known to be associated with the presence of the -lactamases (9).
Moreover, the carbapenem resistance was not associated with ex-
pression of the OXA-51 and AmpC chromosomal -lactamases.
Overall, our data revealed that the presence of OXA-type enzymes
(OXA-24 and/or OXA-58) is sufficient to confer resistance to car-
bapenem in the A. baumannii strains under study, as previously
found (41, 42). Moreover, resistance to doripenem was also asso-
ciated with the presence of the -lactamases OXA-58 (MICs 4
to 8 mg/liter) and OXA-24 (MICs  64 to 64 mg/liter) (com-
pared with MICs for strains of the PFGE-HUI-1 clone of 0.5 to 1
mg/liter).Marti and colleagues (48) analyzed the activity of dorip-
enem against clinical isolates of A. baumannii and concluded that
doripenem was more active than imipenem and meropenem in
strains carrying the OXA-58 -lactamase gene. However, in the
present study, doripenem, imipenem, and meropenem MICs
were high for the clinical strains producing the OXA-24 enzyme.
Quinolone resistance did not vary between the strains under
study and was associated with previously reported mutations in
gyrA and parC (7). Aminoglycoside-resistant isolates of clones
PFGE-ROC-1 and PFGE-HUI-1 showed acetylases known to be
common in A. baumannii strains (AacC1, AphA1, and AadB)
(49).
In conclusion, (i) the clinical strains of Acinetobacter bauman-
nii under study possess efflux systems and other mechanisms
(possibly connected) that enable them to develop resistance to
various antimicrobials and that also have other functions neces-
sary in bacterial pathogenesis. (ii) Overexpression of the AdeABC
system was found to be associated with resistance to glycylcycline
(tigecycline andminocycline) and aminoglycosides (gentamicin),
and possibly other biological functions, in the clinical strains un-
der study. (iii) Hyperexpression of the AdeIJK efflux pump was
significantly associated with resistance to tigecycline and minocy-
cline but did not appear to be involved in other functions related
to the pathogenesis of the bacterium. This efflux pump may be
related to the TetB system and, thus, to minocycline resistance.
(iv) Porins, AmpC -lactamases, and OXA-51 were not involved
in the antimicrobial resistance observed in the present study in the
presence of OXA-type enzymes (OXA-24 and OXA-58). (v) The
OXA-24 and OXA-58 -lactamases were associated with resis-
tance to meropenem, doripenem, and imipenem (especially the
OXA-24 -lactamase). (vi) The presence of the Tet efflux pumps
in A. baumannii isolates was associated with resistance to tetracy-
clines and doxycycline. (vii) Finally, a new RND efflux pumpmay
FIG 5 Relative expression of porin genes by strains of the PFGE-ROC-1OXA-58
and PFGE-ROC-1OXA-24 clones. *, P 0.05 (Student’s t test).
TABLE 5 Interplay of mechanisms of resistance to several antibiotics of the strains of clones PFGE-ROC-1 and PFGE-HUI-1 under study
Antibiotic(s)
Mechanism of resistance
PFGE-ROC-1OXA-58 PFGE-ROC-1OXA-24 PFGE-HUI-1
Tigecycline Overexpression of AdeIJK Overexpression of AdeABC New RND efflux system/TetA(39)
efflux pumpc
Gentamicin Overexpression of AdeABC/acetylases
(aacC1, aphA1, aadB)
Overexpression of AdeABC/acetylases
(aacC1, aphA1, aadB)
Acetylases (aacC1, aphA1, aadB)
Minocycline Overexpression of AdeIJK/TetB efflux
pumps
Overexpression of AdeABCb
Netilmicin, tobramycin, and amikacin Acetylases (aacC1, aphA1, aadB) Acetylases (aacC1, aphA1, aadB) Acetylases (aacC1, aphA1, aadB)
Imipenem, meropenem, and doripenem OXA-58 -lactamase OXA-24 -lactamase
Ciprofloxacin Mutations in gyrA and parC Mutations in gyrA and parC Mutations in gyrA and parC
Doxycycline Overexpression of AdeIJKa/TetB
efflux pumps
TetB efflux pump TetA(39) efflux pumpc
Tetracyclines TetB efflux pump TetB efflux pump TetA(39) efflux pumpc
a Nonsignificantly increased expression relative to strains with doxycycline resistance.
b Only three isolates, 61, 74, and 75.
c Except for strains 421, 422, 423, 424, and 426.
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act in combination with the TetA(39) system to confer resistance
to tigecycline in the absence of the AdeABC efflux pump and over-
expression of the other systems in A. baumannii clinical strains
susceptible to carbapenems.
The main limitation of the study was that we were not able to
study the complex mechanisms of resistance to carbapenems in
strains that did not produce OXA-type enzymes.
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